BCL2 and neoplasm: Moreover, for rG4 in the 5′-UTR of Bcl-2, a known anti-tumor target and apoptosis inhibitor, CRISPR-Cas9-based deletion of the rG4-forming sequence from melanoma cell genome caused no changes in mRNA levels, protein levels, or response to apoptosis-activating compounds compared to unedited cells [52].